.Nature Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean follow-up of 11 months, people along with metastatic stomach growths who received biomarker-matched treatments based on circulating cyst DNA profiling revealed a greater clinical benefit than those acquiring unrivaled treatment.